Testing a new drug for HER2-positive advanced breast cancer
Treatments studied
Part of Cancer clinical trials.
This Phase 3 trial tests DP303c in people with HER2-positive advanced breast cancer that has progressed after prior treatments. It may help by seeing whether the study drug can better control the cancer compared with other options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older and can sign informed consent
- Your breast cancer is advanced and cannot be removed by surgery, or has spread (metastatic), confirmed by pathology testing
- Your tumor is HER2-positive based on specific test results (IHC and, if needed, ISH)
- You’ve had at least two previous hormone/chemo/targeted therapy treatments for advanced or metastatic disease, and the cancer has grown or spread again on the most recent treatment
- Your body is well enough for treatment: ECOG 0–1, adequate organ function, and life expectancy of at least 12 weeks
- If you can become pregnant, you must use reliable birth control during the whole study; pregnancy or breastfeeding is not allowed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called TQB2930 for people with advanced breast cancer that is HER2-positive. It is for those who have already had at least two prior anti-HER2 treatments and are willing to also receive chemotherapy chosen by their doctor.
This trial tests a new antibody-drug conjugate (DP303c) against an existing one, T-DM1, in people with HER2-positive advanced breast cancer who have already been treated with trastuzumab and a taxane. The goal is to see if the new drug works better or has fewer side effects.
This trial tests a new combination of drugs for people with HER2-positive early breast cancer whose tumors did not respond well to the first round of standard targeted therapy plus chemo. The goal is to see if switching to trastuzumab-rezetecan plus pertuzumab or a different chemo combo (nab-paclitaxel, carboplatin, trastuzumab, and pyrotinib) can shrink the tumor before surgery.
This trial tests a combination of two targeted medicines (pyrotinib and trastuzumab) with chemotherapy to treat HER2-positive advanced breast cancer that has returned or spread after stopping trastuzumab.
This trial is testing a new medicine as the first treatment for HER2-positive breast cancer that has spread or cannot be removed. It's for women who have not had chemotherapy for advanced disease.
This Phase 1 trial tests a combination of immune-targeting drugs (a CD40 medicine and a substance that helps immune cells act) plus chemotherapy in people with HER2-negative advanced breast cancer that has progressed. It aims to find a safer dose and see whether the treatment can shrink tumors or slow the cancer.
Hear when a new HER2-positive Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.